Elutia sells BioEnvelope business to Boston Scientific for $88 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
September 9, 2025 8:30 AM EDT- Transaction affirms the strength of Elutias proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -
- Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET -
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (Elutia or the Company), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitive agreement to sell its EluPro and CanGaroo® bioenvelopes, designed to protect patients receiving implantable... More
